NCT07442929 Crystallization of LA and Adjuvant Mixtures in Cerebrospinal Fluid
| NCT ID | NCT07442929 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University Innsbruck |
| Condition | Hydrocephalus |
| Study Type | OBSERVATIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10 participants in total. It began in 2025-09-01 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Different mixtures of local anesthetics or local anesthetics with adjuvants that are known to precipitate in vitro are tested in human cerebrospinal fluid (CSF). CSF is gained from patients with normal pressure hydrocephalus scheduled for elective lumbar puncture. Patients signed an ICF for leftover samples. CSF will be assessed for pH values at different timepoints (t0-t3; 0 to 60 minutes). In a second step six commonly used mixtures of LA with LA or LAs with adjuvants will be mixed using the following mixture ratios: ropivacaine 0.75% + lidocaine 2% (ratio 1:1), ropivacaine 0,75% + mepivacaine 2% (ratio 1:1), ropivacaine 0.75% + chloroprocaine 2% (ratio 1:1), lidocaine 2% + sodium bicarbonate 8.4% (ratio 1:0.1), ropivacaine 0.75% + lidocaine 2% + sodium bicarbonate 8.4% (ratio 1:1:0.1) and ropivacaine 0.75% + dexamethasone (1.5:1). The used mixture ratios are inspired by commonly mixtures described in the current literature and have been proven to precipitate in vitro. For every mixture, a Grade of Crystallisation will be determined at baseline without CSF and then at t0 (immediately) to t3 (60 minutes) every 15 minutes.
Eligibility Criteria
Inclusion Criteria: * Patients with normal pressure hydrocephalus scheduled for elective lumbar puncture. Exclusion Criteria: * Age \< 18 years
Contact & Investigator
Elisabeth Gasteiger, MD PhD
PRINCIPAL INVESTIGATOR
Medical Unicersity Innsbruck
Frequently Asked Questions
Who can join the NCT07442929 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hydrocephalus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07442929 currently recruiting?
Yes, NCT07442929 is actively recruiting participants. Contact the research team at elisabeth.gasteiger@tirol-kliniken.at for enrollment information.
Where is the NCT07442929 trial being conducted?
This trial is being conducted at Innsbruck, Austria.
Who is sponsoring the NCT07442929 clinical trial?
NCT07442929 is sponsored by Medical University Innsbruck. The principal investigator is Elisabeth Gasteiger, MD PhD at Medical Unicersity Innsbruck. The trial plans to enroll 10 participants.